Product approvals

FILE - In this Thursday, Feb. 28, 2013, file photo, a Merck scientist conducts research in West Point, Pa. On Wednesday, Nov. 8, 2017, the Food and Drug Administration approved sales of Merck and Co.'s Prevymix, the first drug to prevent life-threatening infections in adults after a bone marrow transplant. (AP Photo/Matt Rourke, File)
November 08, 2017 - 6:23 pm
TRENTON, N.J. (AP) — U.S. regulators have approved the first drug to prevent life-threatening infections in adults after a bone marrow transplant. The Food and Drug Administration on Wednesday approved sales of Merck and Co.'s Prevymix (PREH'-vih-miss) to prevent infections with cytomegalovirus (sy...
Read More
FILE - In this May 2016 file photo provided by Kite Pharma, cell therapy specialists at the company's manufacturing facility in El Segundo, Calif., prepare blood cells from a patient to be engineered in the lab to fight cancer. On Wednesday, Oct. 18, 2017, the Food and Drug Administration approved sales of the therapy Yescarta, developed by Kite Pharma. It is the second gene therapy for U.S. patients _ the first one for adults _ a custom-made, one-time treatment for certain common types of the blood cancer lymphoma. (Kite Pharma via AP, File)
October 18, 2017 - 8:27 pm
TRENTON, N.J. (AP) — U.S. regulators have approved a second gene therapy for a blood cancer, a one-time, custom-made treatment for aggressive lymphoma in adults. The Food and Drug Administration allowed sales of the treatment from Kite Pharma on Wednesday. It uses the same technology, called CAR-T...
Read More
Dr. Barry Byrne listens to testimony concerning the approval of a potentially breakthrough drug for a form of blindness during a meeting of the The Cellular, Tissue and Gene Therapies advisory committee, Thursday, Oct. 12. 2017, at the FDA in Silver Spring, Md. (AP Photo/Nick Wass)
October 12, 2017 - 7:55 pm
SILVER SPRING, Md. (AP) — A potentially groundbreaking treatment for a rare form of blindness moved one step closer to U.S. approval Thursday, as federal health advisers endorsed the experimental gene therapy for patients with an inherited condition that gradually destroys eyesight. The panel...
Read More
October 09, 2017 - 6:46 am
BEIJING (AP) — China will allow use of some drugs and medical devices based on approval by foreign regulators, the government said Monday, in a move that could help to ease access to its health care market. The step was one of a series announced by Chinese drug regulators to improve access to...
Read More
This April 26, 2017, photo shows the Eli Lilly and Co. corporate headquarters in Indianapolis. On Thursday, Sept. 28, 2017, the Food and Drug Administration approved Eli Lilly's Verzenio, a new medicine for treating adults with a common type of breast cancer that has spread. (AP Photo/Darron Cummings)
September 28, 2017 - 5:27 pm
U.S. regulators have approved a new medicine for treating a common type of breast cancer that has spread to other parts of the body. Eli Lilly's Verzenio (verr-ZEHN'ee-oh) was approved Thursday by the Food and Drug Administration for patients with what's called HR-positive, HER2-negative breast...
Read More
In this July 9, 2015, photo, provided by Novartis Pharmaceuticals Corp., human T cells belonging to cancer patients arrive at Novartis Pharmaceuticals Corp.'s Morris Plains, N.J., facility. The Food and Drug Administration (FDA) approved the first treatment that genetically engineers patients’ own blood cells into an army of leukemia-fighting assassins. Manufacturer Novartis will create those turbocharged cells in this facility and ship them back to hospitals to infuse into patients. (Brent Stirton/Novartis Pharmaceuticals Corp. via AP)
August 30, 2017 - 5:26 pm
WASHINGTON (AP) — Opening a new era in cancer care, U.S. health officials on Wednesday approved a breakthrough treatment that genetically engineers patients' own blood cells into an army of assassins to seek and destroy childhood leukemia. The Food and Drug Administration called the approval...
Read More
This photo provided by the Children’s Hospital of Philadelphia, taken in May 2017, shows Emily Whitehead five years after she became the first pediatric patient in the world to receive an experimental therapy at the hospital that has put her leukemia into long-term remission. Opening a new era in cancer care, the Food and Drug Administration (FDA) approved the first treatment that genetically engineers patients' own blood cells into an army of assassins to seek and destroy childhood leukemia. (Children’s Hospital of Philadelphia via AP)
August 30, 2017 - 12:44 pm
WASHINGTON (AP) — Opening a new era in cancer care, the Food and Drug Administration on Wednesday approved the first treatment that genetically engineers patients' own blood cells into an army of assassins to seek and destroy childhood leukemia. The CAR-T cell treatment developed by Novartis...
Read More
August 30, 2017 - 11:27 am
WASHINGTON (AP) — Opening a new era in cancer care, the Food and Drug Administration on Wednesday approved the first treatment that genetically engineers patients' own blood cells into an army of assassins to seek and destroy childhood leukemia. The CAR-T cell treatment developed by Novartis and...
Read More
FILE - This Thursday, Dec.18, 2014, file photograph, shows the Merck logo on a stained glass panel at a Merck company building in Kenilworth, N.J. A new type of cholesterol drug meant to prevent heart attacks and other complications clearly did so, in an unusually large study whose results were announced Tuesday, Aug. 29, 2017, at a conference of heart specialists. But the daily pill only reduced those complications by 9 percent, leaving drugmaker Merck with a tough call on whether to seek regulatory approval after spending 13 years and likely hundreds of millions of dollars on testing. (AP Photo/Mel Evans, File)
August 29, 2017 - 2:35 am
TRENTON, N.J. (AP) — So-so results for a new type of cholesterol drug have left Merck in a quandary: Does the company try to bring it to market or scrap it? A large, long-term study of the drug showed that it prevents heart attacks and reduces the need for heart procedures, while three similar...
Read More
FILE - This Sept. 21, 2010 file photo shows the interior of the lethal injection facility at San Quentin State Prison in San Quentin, Calif. The California Supreme Court upheld a ballot measure narrowly approved by voters to change the state's dysfunctional death penalty system and speed up executions. The highly anticipated ruling Thursday, Aug. 24, 2017 concerned Proposition 66, a push to "mend not end" capital punishment in California. (AP Photo/Eric Risberg, File)
August 25, 2017 - 9:08 pm
SAN FRANCISCO (AP) — California correctional officials on Friday asked state regulators to approve a revised method of carrying out death sentences after years of delays that have stalled executions since 2006. The new regulations would allow California's death row inmates to be executed using one...
Read More

Pages